Loading clinical trials...
Loading clinical trials...
This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary medicinal product (AMP) in participants ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Fate Therapeutics
NCT06655155 · Systemic Sclerosis (SSc)
NCT07526350 · Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, and more
NCT07413341 · Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome (SS), and more
NCT07228429 · Systemic Sclerosis (SSc), Calcinosis Cutis
NCT06843239 · Systemic Sclerosis (SSc), Scleroderma
Wallace Rheumatic Center
Beverly Hills, California
Providence Medical Foundation
Fullerton, California
University of California Irvine
Irvine, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions